SAS Output

19-NOV-2017 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1425 336 151 71 28 4 07/08/2014 437 218
            1425 336 151 71 28 4      
 
    2 Y 17 S1400G   37 37 20 7 5 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   7 7 7 7 4 1      
        3 S1400B   53 1 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   644 252 112 49 11 0      
            1097 297 139 63 20 1      
 
    3 P 10 S1400I   8 4 2 1 0 0      
        18 S1400G   8 8 4 2 0 0      
        22 S1400F   1 1 1 1 1 1      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            18 13 7 4 1 1      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 3 1 1 0 0 07/31/2014    
            4 3 1 1 0 0      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 32 32 20 7 2 1 03/03/2017 439 219
            32 32 20 7 2 1      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 122 54 24 14 5 1 12/29/2015 434 217
        2 Nivolumab   123 54 23 13 5 1      
            245 108 47 27 10 2      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 77 39 20 10 4 1 05/07/2015 225 95
        2 AFATINIB   73 36 20 8 1 0      
            150 75 40 18 5 1      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 Y 1 Trametinib + Docetaxel 53 44 39 18 7 3 1 10/05/2016 208 92
            44 39 18 7 3 1      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 17 8 2 0 0 01/24/2013 131 53
        6 RT+Pac+Carbo+blinded drug   14 12 4 2 0 0      
            32 29 12 4 0 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 21 21 16 7 2 0 01/24/2013    
            21 21 16 7 2 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   29 17 7 4 1 0 04/01/2015   248
            29 17 7 4 1 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   401 209 116 58 19 6 12/16/2014 452 251
            401 209 116 58 19 6      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   54 4 4 2 2 0 05/14/2008 239 118
            54 4 4 2 2 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   6 3 3 2 0 0 02/29/2016 456 257
            6 3 3 2 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 3 3 1 0 0 10/20/2016 320 143
            4 3 3 1 0 0      
 
    2 E Total Registrations   4 3 3 1 0 0 10/20/2016    
            4 3 3 1 0 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 189 79
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   407 210 113 58 18 6 12/16/2014 452 251
            407 210 113 58 18 6      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   26 21 14 9 2 0 08/03/2016 406 230
            26 21 14 9 2 0      
 

19-NOV-2017 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1400F Non-Match: MEDI4736 + Tremelimumab 1 Registration 02-Oct-17
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Neoadjuvant Therapy 03-Nov-17
  2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17